CTLA4 and cancer: Whether ICI therapy targeting CTLA4 induces similar changes in plaque inflammation in cancer patients is currently unknown and should be investigated in future clinical studies, as our study demonstrates that the inhibition of CTLA4 accelerates the progression of experimental atherosclerosis.